Cargando…

Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine

BACKGROUND: The research of biomarker-treatment interactions is commonly investigated in randomized clinical trials (RCT) for improving medicine precision. The hierarchical interaction constraint states that an interaction should only be in a model if its main effects are also in the model. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Belhechmi, Shaima, Le Teuff, Gwénaël, De Bin, Riccardo, Rotolo, Federico, Michiels, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022294/
https://www.ncbi.nlm.nih.gov/pubmed/36927444
http://dx.doi.org/10.1186/s12859-023-05162-x
_version_ 1784908699148484608
author Belhechmi, Shaima
Le Teuff, Gwénaël
De Bin, Riccardo
Rotolo, Federico
Michiels, Stefan
author_facet Belhechmi, Shaima
Le Teuff, Gwénaël
De Bin, Riccardo
Rotolo, Federico
Michiels, Stefan
author_sort Belhechmi, Shaima
collection PubMed
description BACKGROUND: The research of biomarker-treatment interactions is commonly investigated in randomized clinical trials (RCT) for improving medicine precision. The hierarchical interaction constraint states that an interaction should only be in a model if its main effects are also in the model. However, this constraint is not guaranteed in the standard penalized statistical approaches. We aimed to find a compromise for high-dimensional data between the need for sparse model selection and the need for the hierarchical constraint. RESULTS: To favor the property of the hierarchical interaction constraint, we proposed to create groups composed of the biomarker main effect and its interaction with treatment and to perform the bi-level selection on these groups. We proposed two weighting approaches (Single Wald (SW) and likelihood ratio test (LRT)) for the adaptive lasso method. The selection performance of these two approaches is compared to alternative lasso extensions (adaptive lasso with ridge-based weights, composite Minimax Concave Penalty, group exponential lasso and Sparse Group Lasso) through a simulation study. A RCT (NSABP B-31) randomizing 1574 patients (431 events) with early breast cancer aiming to evaluate the effect of adjuvant trastuzumab on distant-recurrence free survival with expression data from 462 genes measured in the tumour will serve for illustration. The simulation study illustrates that the adaptive lasso LRT and SW, and the group exponential lasso favored the hierarchical interaction constraint. Overall, in the alternative scenarios, they had the best balance of false discovery and false negative rates for the main effects of the selected interactions. For NSABP B-31, 12 gene-treatment interactions were identified more than 20% by the different methods. Among them, the adaptive lasso (SW) approach offered the best trade-off between a high number of selected gene-treatment interactions and a high proportion of selection of both the gene-treatment interaction and its main effect. CONCLUSIONS: Adaptive lasso with Single Wald and likelihood ratio test weighting and the group exponential lasso approaches outperformed their competitors in favoring the hierarchical constraint of the biomarker-treatment interaction. However, the performance of the methods tends to decrease in the presence of prognostic biomarkers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-023-05162-x.
format Online
Article
Text
id pubmed-10022294
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100222942023-03-18 Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine Belhechmi, Shaima Le Teuff, Gwénaël De Bin, Riccardo Rotolo, Federico Michiels, Stefan BMC Bioinformatics Research BACKGROUND: The research of biomarker-treatment interactions is commonly investigated in randomized clinical trials (RCT) for improving medicine precision. The hierarchical interaction constraint states that an interaction should only be in a model if its main effects are also in the model. However, this constraint is not guaranteed in the standard penalized statistical approaches. We aimed to find a compromise for high-dimensional data between the need for sparse model selection and the need for the hierarchical constraint. RESULTS: To favor the property of the hierarchical interaction constraint, we proposed to create groups composed of the biomarker main effect and its interaction with treatment and to perform the bi-level selection on these groups. We proposed two weighting approaches (Single Wald (SW) and likelihood ratio test (LRT)) for the adaptive lasso method. The selection performance of these two approaches is compared to alternative lasso extensions (adaptive lasso with ridge-based weights, composite Minimax Concave Penalty, group exponential lasso and Sparse Group Lasso) through a simulation study. A RCT (NSABP B-31) randomizing 1574 patients (431 events) with early breast cancer aiming to evaluate the effect of adjuvant trastuzumab on distant-recurrence free survival with expression data from 462 genes measured in the tumour will serve for illustration. The simulation study illustrates that the adaptive lasso LRT and SW, and the group exponential lasso favored the hierarchical interaction constraint. Overall, in the alternative scenarios, they had the best balance of false discovery and false negative rates for the main effects of the selected interactions. For NSABP B-31, 12 gene-treatment interactions were identified more than 20% by the different methods. Among them, the adaptive lasso (SW) approach offered the best trade-off between a high number of selected gene-treatment interactions and a high proportion of selection of both the gene-treatment interaction and its main effect. CONCLUSIONS: Adaptive lasso with Single Wald and likelihood ratio test weighting and the group exponential lasso approaches outperformed their competitors in favoring the hierarchical constraint of the biomarker-treatment interaction. However, the performance of the methods tends to decrease in the presence of prognostic biomarkers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-023-05162-x. BioMed Central 2023-03-16 /pmc/articles/PMC10022294/ /pubmed/36927444 http://dx.doi.org/10.1186/s12859-023-05162-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Belhechmi, Shaima
Le Teuff, Gwénaël
De Bin, Riccardo
Rotolo, Federico
Michiels, Stefan
Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine
title Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine
title_full Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine
title_fullStr Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine
title_full_unstemmed Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine
title_short Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine
title_sort favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022294/
https://www.ncbi.nlm.nih.gov/pubmed/36927444
http://dx.doi.org/10.1186/s12859-023-05162-x
work_keys_str_mv AT belhechmishaima favoringthehierarchicalconstraintinpenalizedsurvivalmodelsforrandomizedtrialsinprecisionmedicine
AT leteuffgwenael favoringthehierarchicalconstraintinpenalizedsurvivalmodelsforrandomizedtrialsinprecisionmedicine
AT debinriccardo favoringthehierarchicalconstraintinpenalizedsurvivalmodelsforrandomizedtrialsinprecisionmedicine
AT rotolofederico favoringthehierarchicalconstraintinpenalizedsurvivalmodelsforrandomizedtrialsinprecisionmedicine
AT michielsstefan favoringthehierarchicalconstraintinpenalizedsurvivalmodelsforrandomizedtrialsinprecisionmedicine